Efficacy of the combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of osteoarthritis in multimorbid patients
- Authors: Menshikova I.V.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 29, No 13 (2022)
- Pages: 45-48
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321128
- DOI: https://doi.org/10.18565/pharmateca.2022.13.45-48
- ID: 321128
Cite item
Open Access
Access granted
Abstract
The article discusses the effectiveness of slow-acting drugs containing chondroitin sulfate and glucosamine hydrochloride for the treatment of osteoarthritis (OA). In accordance with the modern concept of the pathogenesis of OA, where a significant place is given to low-intensity inflammation, attention is paid to the anti-inflammatory effect of these substances, as well as the safety of their use in patients with multimorbidity. The results of treatment of a patient with OA of the knee joints and spondylarthrosis, who also suffers from arterial hypertension, overweight and with a history of cancer, are described.
Full Text
About the authors
Irina V. Menshikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: ivmenshikova@mail.ru
Moscow, Russia
References
- Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015-2016 гг. Научнопрактическая ревматология. 2018;56(1):15 21
- McAlindon T.E., Bannuri R.R., Sullivan M.C. et al. OARS! guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. Doi: 10.1016/j. joca.2014.01.003.
- Bruyere O, Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. Doi: 10.1016/j. semarthrit.2019.04.008.
- Dell'Isola A., Pihl K., Turkiewicz A., et al. Risk of comorbidities following physician-diagnosed knee or hip osteoarthritis: A register-based cohort study. Arthritis Care Res (Hoboken). 2022;74(10): 1689-95. Doi: 10.1002/ acr.24717.
- Muckelt P.E, Roos E.M., Stokes M., et al.Comorbidities and their link with individual health status: A cross-sectional analysis of 23,892 people with knee and hip osteoarthritis from primary care. J Comorb. 2020;10:2235042X20920456. doi: 10.1177/2235042X20920456.
- Constantino de Campos G., Mundi R., Whittington C., et al. Osteoarthritis, mobility-related comorbidities and mortality: An overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020;12:1759720X20981219. doi: 10.1177/1759 720X2 09812 19.
- Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита. Современная ревматология. 2019;13(2):4-8.
- Simental-Mendia M., Sanchez-Garcia A., Vilchez-Cavazos F., et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheum Int. 2018 38(8):1413-28. doi: 10.1007/s00296-018-4077-2.
- Navarro S.L., White E., Kantor et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One, 2015;10(2):e0117534. doi: 10.1371/journal.pone.0117534.
- Navarro S.L., Herrero M., Martinez H., et al. Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2020;19(2):190-201. doi: 10.2174/1871523 018666190115094512.
- King D.E., Xiang J. Glucosamine/chondroitin and mortality in US NHAHES cohort. J Am Board Fam Med. 2020;33(6):842-47. Doi: 10.3122/ jabfm.2020.06.200110.
- Khan A., Mannan Vij., Pervaiz M.A., et al. The Role of Glucosamine and Chondroitin Sulfate in the Prevention of Colorectal Cancer: A Systematic Review. Cureus. 2022;14(5):e25401. doi: 10.7759/cureus.25401.
- Henrotin Y., Lambert C., Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycansagainst synovialinflammation. Semin Arthritis Rheum. 2014;43(5):579-87. doi: 10.1016/j.semarthrit.2013.10/005.
- Fransen M., Agaliotis M., Nair L., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5): 851-58. doi: 10.1136/annrheumdis-2013-203954.
- Yang W., Sun C., He S.Q., et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis - A systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085-93. Doi: 10.1007/ s11606-021-06755-z.
- Алексеева Л.И., Шарапова Е.П., Кашеварова Н.Г., Таскина Е.А., Аникин С.Г., Лила А.М., Мендель О.И. Многоцентровое проспективное наблюдательное исследование по применению препаратов АРТРА МСМ Форте и АРТРА у пациентов с остеоартритом коленных и/ или тазобедренных суставов и/или с болью в нижней части спины (предварительные результаты). Трудный пациент. 2018;16:34- 41.
Supplementary files
